Intelligence · Clinical Development
Pipeline search results
Programs matching “control” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 67 pipeline programs matching "control" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
REC611-IIT-1
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Prevention of COVID-19 Caused by SARS-CoV-2
1 trial -
Safety for A Phase 1, Randomized, Double-B…
Lacuna Pharma Pty Ltd
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses and Food Effect of Leucettinib-21 in Healthy Male Subjects, followed by an open single dose of Leucettinib-21 in Down Syndrome individuals, and patients with Alzheimer’s disease
1 trial -
TGD001 SAD study in healthy volunteers
Lacuna Pharma Pty Ltd
A Phase I randomized, double-blind, placebo-controlled study to assess the safety and pharmacokinetics of single-ascending doses of TGD001 in healthy volunteers
1 trial -
[11C]OMAR
BRIGHT MINDS BIOSCIENCES INC.
Healthy Control
1 trial -
placebo control
Takeda
Hemophilia
1 trial -
Control: Femoral perineural local anesthetic infusion
Summit Therapeutics
Postoperative Pain Following Knee Arthroplasty
1 trial -
Oxycodone Hydrochloride
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Analgesia, Patient-Controlled
1 trial -
Standard BP control
The First People's Hospital of Lianyungang
Hypertension
1 trial -
Xolair 75 mg solution for injection in pre-filled syringe
Pari Pharma GmbH
Well controlled severe allergic asthma
1 trial -
a control group
The First People's Hospital of Lianyungang
Disorder of Stomach Function and Feeding Problems in Newborn
1 trial -
early standardised rhythm control
Rhythm Pharmaceuticals Netherlands B.V.
Atrial Fibrillation
1 trial -
intravenous sufentanil
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Analgesia, Patient-Controlled
1 trial -
Control
United Therapeutics Europe Ltd
Body Weight
1 trial -
Control (Standard treatment)
Grace Therapeutics
Moisture Associated Skin Damage
1 trial -
Control lidocaine cream
The First People's Hospital of Lianyungang
Atopic Dermatitis
1 trial -
Controlled low central venous pressure (CLCVP) technology
The First People's Hospital of Lianyungang
Acute Kidney Injury
1 trial -
Intensive BP control
Chinese University of Hong Kong
Primary Hypertension
1 trial -
Rehabilitation Therapy as part of Standard of Care (Control)
BRIGHT MINDS BIOSCIENCES INC.
Acute Stroke
1 trial -
Sana Device (Control)
Sana Biotechnology
Fibromyalgia
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.